| 3.3 0.11 (3.45%) | 05-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.91  |
1-year : | 4.57 |
| Resists | First : | 3.34 |
Second : | 3.91 |
| Pivot price | 3 |
|||
| Supports | First : | 2.87 |
Second : | 2.58 |
| MAs | MA(5) : | 3.12 |
MA(20) : | 3 |
| MA(100) : | 2.48 |
MA(250) : | 2.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 67.5 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 3.65 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTX ] has closed below upper band by 16.2%. Bollinger Bands are 8.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.32 - 3.33 | 3.33 - 3.34 |
| Low: | 3.09 - 3.1 | 3.1 - 3.12 |
| Close: | 3.28 - 3.3 | 3.3 - 3.32 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Thu, 28 May 2026
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Tue, 19 May 2026
NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan
Fri, 15 May 2026
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - Sahm
Tue, 12 May 2026
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan
Fri, 17 Apr 2026
What date does Nkarta's (NKTX) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
Fri, 17 Apr 2026
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 80.5 (%) |
| Shares Short | 5,270 (K) |
| Shares Short P.Month | 5,530 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -2.45 |
| PEG Ratio | 0 |
| Price to Book value | 0.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|